Slide background
Slide background




Safe design and operation of on site generation of oxygen 93% for medical use

ID 1668 | | Visite: 4408 | Documenti Chemicals EntiPermalink: https://www.certifico.com/id/1668

Temi: Chemicals , EIGA



Safe design and operation of on site generation of oxygen 93% for medical use

Oxygen for medicinal use is a prime requirement for all healthcare facilities for both the treatment of patients with respiratory disease and for providing additional oxygen to patients being treated within the facility.

For those hospitals and clinics, where the demand is higher, oxygen is normally distributed throughout the facility using a medical gas pipeline system.

The design requirements for the supply source used to supply medical oxygen to the pipeline system are detailed in the standard, EN ISO 7396-1 Medical gas pipeline systems; Pipeline systems for compressed medical gases and vacuum.

Two different products are included in the standard:

- Medicinal oxygen supplied from liquid oxygen vessels and/or gaseous oxygen cylinders; and
- Oxygen 93 manufactured on-site within the healthcare facility, using an oxygen concentrator unit.

Medicinal oxygen supplied either in cylinders or as a cryogenic liquid, is required to be manufactured by an approved supplier with a manufacturers licence (to demonstrate compliance with guidelines detailed in the European Commission’s Guide to Good Manufacturing Practice (GMP))

Within the European Union, the supplier of medical oxygen is required to hold a marketing authorisation in accordance with Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, detailing the clinical indications and contraindications and specific warnings for the safe use of the product.

The specification of this medical oxygen is detailed in the European Pharmacopoeia monograph for medical oxygen, which specifies a minimum purity of 99.5% oxygen.

The quality, safety and efficacy of the medical oxygen are ensured by the medical gas supplier through a quality management system under the responsibility of a qualified person.

Oxygen 93 can be manufactured on-site within the healthcare facility, under the responsibility of the healthcare facility pharmacist, using an oxygen 93 supply system and meeting the appropriate and specific quality and safety criteria for medicinal products prepared in Pharmacies (see Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme Guide PE010-4 Guideline to good practices for the preparation of medicinal products in healthcare establishment).

Oxygen 93 is not being ‘put on the market’, so it currently falls outside the regulation for the manufacture and supply of medicinal product Directive 2001/83/EC.

Oxygen 93 concentrator units are covered by the requirements for CE marking in accordance with the Medical Device Directive, (Council Directive 93/42/EEC of 14 June 1993 concerning medical devices).

The specification of the oxygen manufactured using an oxygen 93 supply system is detailed in the European Pharmacopoeia monograph for oxygen 93, which specifies the oxygen content to be between 90% and 96% and gives appropriate limits and analysis methods of other possible contaminants during the production.

As the oxygen 93 is produced by adsorbing the nitrogen from ambient air, the major contaminant in oxygen 93 is argon, which can be present up to 5%.

When the oxygen 93% monograph was introduced it was stated that the benefits of PSA oxygen (oxygen 93 per cent) are to allow production and supply of oxygen at sites where access for cylinder and liquid oxygen supply is difficult or impossible. PSA concentrators are in use in a number of fields particularly by the military (field hospitals).

The quality of the gas is very much dependent upon the performance of the equipment that produces it.

At the time of preparation of this publication, oxygen 93 is not licensed under a marketing authorisation, thus it is not evaluated by regulatory authorities and thus it cannot be considered as “equivalent medicine” for the oxygen.

EIGA 2015



Tags: Chemicals EIGA

Articoli correlati

Ultimi archiviati Chemicals

Cattura
Apr 22, 2021 13

III Rapporto ECHA sulla strategia di regolamentazione integrata 2020

III Rapporto ECHA sulla strategia di regolamentazione integrata Integrated Regulatory Strategy Annual Report Helsinki, 21 aprile 2021 Il terzo rapporto dell'ECHA sulla strategia di regolamentazione integrata fornisce le ultime novità sul lavoro dell'Agenzia per identificare e gestire le sostanze… Leggi tutto
Apr 16, 2021 72

Seconda relazione consuntiva CE: furani e i bifenili policlorurati - 2007

Seconda relazione consuntiva CE: furani e i bifenili policlorurati - 2007 Comunicazione della Commissione al Consiglio, al Parlamento Europeo e al Comitato economico e sociale europeo relativa all’attuazione della strategia comunitaria sulle diossine, i furani e i bifenili policlorurati (COM(2001)… Leggi tutto
Decisione UE 2021 592
Apr 13, 2021 47

Decisione (UE) 2021/592 del Consiglio del 7 aprile 2021

Decisione (UE) 2021/592 del Consiglio del 7 aprile 2021 relativa alla presentazione, a nome dell’Unione europea, di una proposta di inclusione del clorpirifos nell’allegato A della convenzione di Stoccolma sugli inquinanti organici persistenti GU L 125/52 del 13.04.2021 Entrata in vigore:… Leggi tutto
Report EFSA 2019 Pesticide
Apr 12, 2021 65

Reports EFSA on pesticide residue analysis performed in 2019

Reports EFSA on pesticide residue analysis performed in 2019 EFSA, 07 Aprile 2021 Pubblicato l’ultimo rapporto sui residui di pesticidi negli alimenti nell’Unione europea, uno spaccato dei tenori di residui riscontrati nell’intero territorio in un paniere di prodotti di largo consumo. Nel 2019 sono… Leggi tutto
Apr 09, 2021 95

Protocollo inquinanti organici persistenti della convenzione del 1979

Protocollo sugli inquinanti organici persistenti della convenzione del 1979 sull'inquinamento atmosferico transfrontaliero a grande distanza (GU L 81, 19.3.2004) Collegati
La Convenzione di Stoccolma: Inquinanti organici persistentiRegolamento (UE) 2019/1021 (POPs) | Consolidato
Leggi tutto
Apr 09, 2021 111

Comunicazione 2001/C 322/02

Comunicazione 2001/C 322/02 Comunicazione della Commissione al Consiglio, al Parlamento europeo e al Comitato economico e sociale - Strategia comunitaria sulle diossine, i furani e i bifenili policlorurati 2001/C 322/02 (COM/2001/0593 definitivo) (GU n. 322 del 17.11.2001) Leggi tutto

Più letti Chemicals

Regolamento  CE  n  178 2002
Feb 28, 2020 43766

Regolamento (CE) N. 178/2002

Regolamento (CE) n. 178/2002 Regolamento (CE) n. 178/2002 del Parlamento europeo e del Consiglio del 28 gennaio 2002 che stabilisce i principi e i requisiti generali della legislazione alimentare, istituisce l'Autorità europea per la sicurezza alimentare e fissa procedure nel campo della sicurezza… Leggi tutto